Trial · NCT03175367
Results by group81
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 81
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 16 (Intent-to-Treat [ITT] Estimand) | Group A: Placebo SC QW (DBTP) | 8.8 | Standard Error 6.4 | Percent Change | |
| Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 16 (Intent-to-Treat [ITT] Estimand) | Group A: Evinacumab 300 mg SC Q2W (DBTP) | -29.7 | Standard Error 6.4 | Percent Change | |
| Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 16 (Intent-to-Treat [ITT] Estimand) | Group A: Evinacumab 300 mg SC QW (DBTP) | -44.0 | Standard Error 6.3 | Percent Change | |
| Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 16 (Intent-to-Treat [ITT] Estimand) | Group A: Evinacumab 450 mg SC QW (DBTP) | -47.2 | Standard Error 6.2 | Percent Change | |
| Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 16 (Intent-to-Treat [ITT] Estimand) | Group B: Placebo IV Q4W (DBTP to OLTP) | 0.6 | Standard Error 6.6 | Percent Change | |
| Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 16 (Intent-to-Treat [ITT] Estimand) | Group B: Evinacumab 5 mg/kg IV Q4W (DBTP to OLTP) | -23.5 | Standard Error 6.6 | Percent Change | |
| Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 16 (Intent-to-Treat [ITT] Estimand) | Group B: Evinacumab 15 mg/kg IV Q4W (DBTP to OLTP) | -49.9 | Standard Error 6.1 | Percent Change | |
| Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 16 (ITT Estimand) | Group A: Placebo SC QW (DBTP) | 6.7 | Standard Error 5.1 | Percent Change | |
| Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 16 (ITT Estimand) | Group A: Evinacumab 300 mg SC Q2W (DBTP) | -19.9 | Standard Error 5.1 | Percent Change | |
| Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 16 (ITT Estimand) | Group A: Evinacumab 300 mg SC QW (DBTP) | -35.2 | Standard Error 5.1 | Percent Change | |
| Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 16 (ITT Estimand) | Group A: Evinacumab 450 mg SC QW (DBTP) | -38.8 | Standard Error 4.9 | Percent Change | |
| Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 16 (ITT Estimand) | Group B: Placebo IV Q4W (DBTP to OLTP) | -3.8 | Standard Error 4.7 | Percent Change | |
| Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 16 (ITT Estimand) | Group B: Evinacumab 5 mg/kg IV Q4W (DBTP to OLTP) | -20.4 | Standard Error 4.6 | Percent Change | |
| Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 16 (ITT Estimand) | Group B: Evinacumab 15 mg/kg IV Q4W (DBTP to OLTP) | -43.2 | Standard Error 4.3 | Percent Change | |
| Percent Change From Baseline in Apo B at Week 24 (ITT Estimand) | Group B: Placebo IV Q4W (DBTP to OLTP) | 5.9 | Standard Error 6.0 | Percent Change | |
| Percent Change From Baseline in Apo B at Week 24 (ITT Estimand) | Group B: Evinacumab 5 mg/kg IV Q4W (DBTP to OLTP) | -15.9 | Standard Error 5.9 | Percent Change | |
| Percent Change From Baseline in Apo B at Week 24 (ITT Estimand) | Group B: Evinacumab 15 mg/kg IV Q4W (DBTP to OLTP) | -34.5 | Standard Error 5.6 | Percent Change | |
| Percent Change From Baseline in Non High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 16 (ITT Estimand) | Group A: Placebo SC QW (DBTP) | 8.0 | Standard Error 5.4 | Percent Change | |
| Percent Change From Baseline in Non High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 16 (ITT Estimand) | Group A: Evinacumab 300 mg SC Q2W (DBTP) | -31.3 | Standard Error 5.4 | Percent Change | |
| Percent Change From Baseline in Non High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 16 (ITT Estimand) | Group A: Evinacumab 300 mg SC QW (DBTP) | -45.8 | Standard Error 5.3 | Percent Change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03175367/results